Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons

INTRODUCTION: Clinical trials conducted in patients with type 2 diabetes (T2DM) treated with glucose-lowering drugs and examining cardiovascular-related outcomes have yielded mixed results. In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Balijepalli, Chakrapani, Shirali, Rohan, Kandaswamy, Prashanth, Ustyugova, Anastasia, Pfarr, Egon, Lund, Søren S., Druyts, Eric
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064600/
https://ncbi.nlm.nih.gov/pubmed/29949014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0456-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars